In May 2025, Illumina, Inc., and Ovation.io, Inc., announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies
Because no randomized combination study exists, ratio and dose remain extrapolations
In this issue, were diving deeper into the potential benefits of GLP-1 agonist medicationswidely known for treating diabetes and weight managementon neurological, cardiovascular, and immune system health
Starting with lower doses and gradually increasing them often provides the best experience
Greek yogurt, cottage cheese, chicken breast, fish, eggs, and whey protein shakes are high-density protein sources that deliver significant protein in relatively small volumes
Most GLP-1 side effects are mild to moderatebut that doesnt mean they arent uncomfortable or inconvenient